These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 12975461

  • 1. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    Weng WK, Levy R.
    J Clin Oncol; 2003 Nov 01; 21(21):3940-7. PubMed ID: 12975461
    [Abstract] [Full Text] [Related]

  • 2. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
    Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A.
    J Clin Oncol; 2008 Apr 10; 26(11):1789-96. PubMed ID: 18347005
    [Abstract] [Full Text] [Related]

  • 3. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7046-53. PubMed ID: 17145827
    [Abstract] [Full Text] [Related]

  • 4. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
    Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA.
    J Clin Oncol; 2005 Jan 20; 23(3):474-81. PubMed ID: 15659493
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R.
    J Clin Oncol; 2004 Dec 01; 22(23):4717-24. PubMed ID: 15483014
    [Abstract] [Full Text] [Related]

  • 6. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ.
    J Clin Oncol; 2007 Aug 20; 25(24):3712-8. PubMed ID: 17704420
    [Abstract] [Full Text] [Related]

  • 7. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 8. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
    Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S, Ennishi D, Asai H, Yokoyama M, Kojima K, Hatake K.
    Clin Cancer Res; 2009 May 15; 15(10):3624-32. PubMed ID: 19417028
    [Abstract] [Full Text] [Related]

  • 9. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB.
    Clin Cancer Res; 2008 Jul 15; 14(14):4650-7. PubMed ID: 18628480
    [Abstract] [Full Text] [Related]

  • 10. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.
    Ai Zheng; 2007 Aug 15; 26(8):837-42. PubMed ID: 17697543
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
    Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, Suzuki T, Mori M, Kasai M, Cronier D, Wooldridge JE, Koshiji M.
    Cancer Sci; 2011 Feb 15; 102(2):432-8. PubMed ID: 21205069
    [Abstract] [Full Text] [Related]

  • 12. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 15; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 13. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan 15; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N, Hayama M, Okamoto M, Khori M, Higashihara M, Tamaru J, Hirano M.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [Abstract] [Full Text] [Related]

  • 15. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
    Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, Smith MR, Link BK, Wooldridge JE, Ganjoo KN.
    Clin Cancer Res; 2012 Mar 01; 18(5):1395-403. PubMed ID: 22223529
    [Abstract] [Full Text] [Related]

  • 16. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA.
    J Clin Oncol; 2005 Feb 20; 23(6):1088-95. PubMed ID: 15657401
    [Abstract] [Full Text] [Related]

  • 17. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Chen Z, Freedman MS.
    Clin Immunol; 2008 Aug 20; 128(2):219-27. PubMed ID: 18501678
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J.
    Acta Oncol; 2008 Aug 20; 47(6):1029-36. PubMed ID: 18607857
    [Abstract] [Full Text] [Related]

  • 19. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J, Briones J.
    Exp Hematol; 2008 Jan 20; 36(1):69-77. PubMed ID: 17959301
    [Abstract] [Full Text] [Related]

  • 20. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
    Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M.
    J Clin Oncol; 2010 Oct 10; 28(29):4480-4. PubMed ID: 20697092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.